[1] |
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020,382(18):1708⁃1720. doi: 10.1056/NEJMoa2002032.
|
[2] |
Recalcati S. Cutaneous manifestations in COVID⁃19: a first perspective[J]. J Eur Acad Dermatol Venereol, 2020,34(5):e212⁃e213. doi: 10.1111/jdv.16387.
|
[3] |
Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID⁃19⁃associated dermatologic manifestations: an international registry of 716 patients from 31 countries[J]. J Am Acad Dermatol, 2020,83(4):1118⁃1129. doi: 10.1016/j.jaad. 2020.06.1016.
|
[4] |
杜娟, 林岚梅, 徐金华, 等. 新阶段因新冠感染诱发的皮肤损害及对策[J]. 中国皮肤性病学杂志, 2023,37(2):123⁃127. doi: 10.13735/j.cjdv.1001⁃7089.202212094.
|
[5] |
Mohseni Afshar Z, Babazadeh A, Hasanpour A, et al. Dermatological manifestations associated with COVID⁃19: a comprehensive review of the current knowledge[J]. J Med Virol, 2021,93(10):5756⁃5767. doi: 10.1002/jmv.27187.
|
[6] |
Shimizu H, Matsumoto H, Sasajima T, et al. New⁃onset dermatomyositis following COVID⁃19: a case report[J]. Front Immunol, 2022,13:1002329. doi: 10.3389/fimmu.2022.1002329.
|
[7] |
Sharquie KE, Jabbar RI. COVID⁃19 infection is a major cause of acute telogen effluvium[J]. Ir J Med Sci, 2022,191(4):1677⁃1681. doi: 10.1007/s11845⁃021⁃02754⁃5.
|
[8] |
Kocatürk E, Muñoz M, Elieh⁃Ali⁃Komi D, et al. How infection and vaccination are linked to acute and chronic urticaria: a special focus on COVID⁃19[J]. Viruses, 2023,15(7):1585. doi: 10.3390/v15071585.
|
[9] |
邓维, 张高磊, 陈见友, 等. 61例儿童新型冠状病毒感染的皮肤表现分析[J]. 中华皮肤科杂志, 2023,56(12):1154⁃1157. doi: 10.35541/cjd.20220910.
|
[10] |
Oztas Kara R, Sevimli Dikicier B. Clinical features and outcomes of acute versus chronic urticaria triggered by COVID⁃19 infection[J]. Adv Skin Wound Care, 2024,37(4):1⁃5. doi: 10.1097/ASW.0000000000000118.
|
[11] |
Mobasheri L, Nasirpour MH, Masoumi E, et al. SARS⁃CoV⁃2 triggering autoimmune diseases[J]. Cytokine, 2022,154:155873. doi: 10.1016/j.cyto.2022.155873.
|
[12] |
Kocatürk E, Salman A, Cherrez⁃Ojeda I, et al. The global impact of the COVID⁃19 pandemic on the management and course of chronic urticaria[J]. Allergy, 2021,76(3):816⁃830. doi: 10.1111/all.14687.
|
[13] |
Cosansu NC, Yuksekal G, Kutlu O, et al. The change in the frequency and severity of facial dermatoses and complaints in healthcare workers during the COVID⁃19[J]. J Cosmet Dermatol, 2022,21(8):3200⁃3205. doi: 10.1111/jocd.15044.
|
[14] |
Singh GK, Mitra B, Bhatnagar A, et al. Unusual spurts of rosacea like dermatoses, posing a diagnostic dilemma during Covid⁃19 pandemic: a cross⁃sectional, observational study from a tertiary care centre[J]. Indian J Dermatol, 2021,66(4):401⁃404. doi: 10.4103/ijd.IJD_759_20.
|
[15] |
Nguyen B, Tosti A. Alopecia areata after COVID⁃19 infection and vaccination: a cross⁃sectional analysis[J]. J Eur Acad Dermatol Venereol, 2023,37(1):e7⁃e8. doi: 10.1111/jdv.18491.
|
[16] |
Kim J, Hong K, Gómez Gómez RE, et al. Lack of evidence of COVID⁃19 being a risk factor of alopecia areata: results of a national cohort study in South Korea[J]. Front Med (Lausanne), 2021,8:758069. doi: 10.3389/fmed.2021.758069.
|
[17] |
Rajabi F, Drake LA, Senna MM, et al. Alopecia areata: a review of disease pathogenesis[J]. Br J Dermatol, 2018,179(5):1033⁃1048. doi: 10.1111/bjd.16808.
|
[18] |
Ghafoor R, Ali SM, Patil A, et al. Association of androgenetic alopecia and severity of coronavirus disease 2019[J]. J Cosmet Dermatol, 2022,21(3):874⁃879. doi: 10.1111/jocd.14683.
|
[19] |
Wambier CG, Goren A, Vaño⁃Galván S, et al. Androgen sensitivity gateway to COVID⁃19 disease severity[J]. Drug Dev Res, 2020,81(7):771⁃776. doi: 10.1002/ddr.21688.
|
[20] |
Otsuka Y, Nakano Y, Hagiya H, et al. Recovery from alopecia after COVID⁃19[J]. Cureus, 2022,14(1):e21160. doi: 10.7759/cureus.21160.
|
[21] |
Elgardt I, Carmi O, Levy Y. IgA nephropathy (Henoch⁃Schönlein purpura) associated with recent COVID⁃19 infection[J]. Isr Med Assoc J, 2022,24(11):697⁃698.
|
[22] |
Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID⁃19 infection: a report of five cases[J]. Transl Res, 2020,220:1⁃13. doi: 10.1016/j.trsl.2020.04.007.
|
[23] |
Chularojanamontri L, Tuchinda P, Rujitharanawong C, et al. New⁃onset and exacerbated skin diseases after COVID⁃19 infection: a systematic review[J]. J Dermatol, 2022,49(11):e419⁃e421. doi: 10.1111/1346⁃8138.16501.
|
[24] |
陈瑞, 梁文, 蒋雨薇, 等. 新型冠状病毒肺炎疫情期间医护人员皮肤损伤流行病学调查及特征分析[J]. 中华皮肤科杂志, 2020,53(11):923⁃927. doi: 10.35541/cjd.20200356.
|
[25] |
李珊珊, 梁宇, 潘志婷, 等. "后疫情时期"新冠肺炎患者创伤后应激障碍现状及影响因素分析[J]. 中国医院管理, 2021,41(8):79⁃82.
|
[26] |
杨敬铭, 王鑫, 刘丽改, 等. 感染新型冠状病毒患者的焦虑特质与心理健康的相关性研究[J]. 首都医科大学学报, 2023,44(4):609⁃613. doi: 10.3969/j.issn.1006⁃7795.2023.04.017.
|
[27] |
Kyrou I, Karteris E, Robbins T, et al. Polycystic ovary syndrome (PCOS) and COVID⁃19: an overlooked female patient population at potentially higher risk during the COVID⁃19 pandemic[J]. BMC Med, 2020,18(1):220. doi: 10.1186/s12916⁃020⁃01697⁃5.
|
[28] |
Seyed Resuli A, Bezgal M. Subacute thyroiditis in COVID⁃19 patients[J]. Ear Nose Throat J, 2022,101(8):501⁃505. doi: 10.1177/01455613211012114.
|
[29] |
Xu Y, Gao R, Zhu G, et al. Genetic variation of allergic disease is associated with the susceptibility to COVID⁃19[J]. J Infect, 2022,84(5):e92⁃e93. doi: 10.1016/j.jinf.2022.01.015.
|
[30] |
Chhapola Shukla S. ACE2 expression in allergic airway disease may decrease the risk and severity of COVID⁃19[J]. Eur Arch Otorhinolaryngol, 2021,278(7):2637⁃2640. doi: 10.1007/s00405⁃020⁃06408⁃7.
|
[31] |
窦进法, 王建波, 张帅, 等. 新型冠状病毒感染疫情期间接受生物制剂治疗的中重度斑块状银屑病患者病情变化及影响因素分析: 单中心横断面研究[J]. 中华皮肤科杂志, 2024,57(8):739⁃742. doi: 10.35541/cjd.20230167.
|
[32] |
Cazzato G, Cascardi E, Colagrande A, et al. SARS⁃CoV⁃2 and skin: new insights and perspectives[J]. Biomolecules, 2022,12(9):1212. doi: 10.3390/biom12091212.
|
[33] |
Barda N, Dagan N, Ben⁃Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid⁃19 vaccine in a nationwide setting[J]. N Engl J Med, 2021,385(12):1078⁃1090. doi: 10.1056/NEJMoa2110475.
|
[34] |
Sun Q, Fathy R, McMahon DE, et al. COVID⁃19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide[J]. Dermatol Clin, 2021,39(4):653⁃673. doi: 10.1016/j.det. 2021.05.016.
|
[35] |
El⁃Qushayri AE, Nardone B. Psoriasis exacerbation after COVID⁃19 vaccines: a brief report of the reported cases[J]. Dermatol Ther, 2022,35(12):e15900. doi: 10.1111/dth.15900.
|